BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31920463)

  • 1. Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells.
    Yang Y; Ding L; Zhou Q; Fen L; Cao Y; Sun J; Zhou X; Liu A
    Cancer Cell Int; 2020; 20():9. PubMed ID: 31920463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
    Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
    J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
    Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
    Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
    Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
    Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting aurora kinase A inhibits hypoxia-mediated neuroblastoma cell tumorigenesis.
    Romain CV; Paul P; Lee S; Qiao J; Chung DH
    Anticancer Res; 2014 May; 34(5):2269-74. PubMed ID: 24778030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
    Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
    Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
    Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses.
    Meng B; Zhao X; Jiang S; Xu Z; Li S; Wang X; Ma W; Li L; Liu D; Zheng J; Peng H; Shi M
    Front Immunol; 2023; 14():1182601. PubMed ID: 37781397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo.
    Tanaka H; Nakashiro K; Iwamoto K; Tokuzen N; Fujita Y; Shirakawa R; Oka R; Goda H; Hamakawa H
    Oral Oncol; 2013 Jun; 49(6):551-9. PubMed ID: 23481312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
    Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N
    Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers.
    Katsha A; Arras J; Soutto M; Belkhiri A; El-Rifai W
    Mol Oncol; 2014 Dec; 8(8):1419-28. PubMed ID: 24953013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.
    Liu X; Li Z; Song Y; Wang R; Han L; Wang Q; Jiang K; Kang C; Zhang Q
    Oncotarget; 2016 May; 7(22):33152-64. PubMed ID: 27121204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.
    Carol H; Boehm I; Reynolds CP; Kang MH; Maris JM; Morton CL; Gorlick R; Kolb EA; Keir ST; Wu J; Wozniak AE; Yang Y; Manfredi M; Ecsedy J; Wang J; Neale G; Houghton PJ; Smith MA; Lock RB
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1291-304. PubMed ID: 21448591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
    Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
    Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
    Yen CC; Chen SC; Hung GY; Wu PK; Chua WY; Lin YC; Yen CH; Chen YC; Wang JY; Yang MH; Chao Y; Chang MC; Chen WM
    Int J Oncol; 2019 Oct; 55(4):938-948. PubMed ID: 31485600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
    Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
    Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
    Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
    Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.